Search Result

Results for "

glycoprotein IIb/IIIa receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Glycoprotein VI (1) Antibiotic (1) Bacterial (1) Cytochrome P450 (1) Integrin (13)
By Research Areas:	Cancer (1) Cardiovascular Disease (14) Infection (1) Inflammation/Immunology (1) Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Transmembrane Glycoprotein Glycoprotein VI P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9934

Abciximab 1 Publications Verification C7E3	Integrin	Cardiovascular Disease
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a **glycoprotein (GP) IIb/IIIa** inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .

HY-B0686B

Eptifibatide acetate Maximum Cited Publications 7 Publications Verification	Integrin	Cardiovascular Disease
Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity .

HY-B0686

Eptifibatide Maximum Cited Publications 7 Publications Verification	Integrin	Cardiovascular Disease
Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity .

HY-10309

Sibrafiban RO 48-3657	Integrin	Cardiovascular Disease
Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective **glycoprotein IIb/IIIa receptor** antagonist. Sibrafiban inhibits platelet aggregation .

HY-10308

Lefradafiban	Others	Metabolic Disease
Lefradafiban is an orally active **glycoprotein IIb/IIIa receptor** antagonist. Lefradafiban can be metabolized to its active form, Fradafiban, a non-peptide GP IIb/IIIa receptor antagonist .

HY-10307

Roxifiban	Integrin	Cardiovascular Disease
Roxifiban is a platelet glycoprotein (GP) IIb/IIIa receptor inhibitor that can be used in the study of angina .

HY-B0686A

Eptifibatide monoacetate	Integrin	Cardiovascular Disease
Eptifibatide monoacetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity .

HY-10307A

Roxifiban acetate DMP 754	Integrin	Cardiovascular Disease
Roxifiban (acetate) is the acetate form of Roxifiban (HY-10307). Roxifiban (acetate) is a platelet glycoprotein (GP) IIb/IIIa receptor inhibitor that can be used in research related to angina .

HY-125668

Ro 43-5054	Integrin	Cancer
Ro 43-5054 is a platelet glycoprotein IIb-IIIa receptor antagonist. Ro 43-5054 can be used in the research of early reocclusion after thrombolytic therapy .

HY-111348

Lamifiban Ro 44-9883	Integrin	Cardiovascular Disease
Lamifiban is a nonpeptide **glycoprotein IIb/IIIa receptor and platelet aggregation** antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes .

HY-B0686BR

Eptifibatide (acetate) (Standard)	Integrin	Cardiovascular Disease
Eptifibatide (acetate) (Standard) is the analytical standard of Eptifibatide (acetate). This product is intended for research and analytical applications. Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .

HY-108881R

Troleandomycin (Standard)	Antibiotic Cytochrome P450 Bacterial	Infection Inflammation/Immunology
Eptifibatide (acetate) (Standard) is the analytical standard of Eptifibatide (acetate). This product is intended for research and analytical applications. Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .

HY-111348A

Lamifiban TFA	Integrin	Cardiovascular Disease
Lamifiban TFA is a nonpeptide **glycoprotein IIb/IIIa receptor and platelet aggregation** antagonist. Lamifiban TFA in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban TFA is promising for research of acute coronary syndromes .

HY-125615

DMP 728 methanesulfonate	Glycoprotein VI	Cardiovascular Disease Others
DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries .

HY-10309R

Sibrafiban (Standard) RO 48-3657 (Standard)	Integrin	Cardiovascular Disease
Sibrafiban (Standard) is the analytical standard of Sibrafiban. This product is intended for research and analytical applications. Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation .

HY-167686

Variabilin Homopisatin	Integrin	Cardiovascular Disease
Variabilin (Homopisatin) is a potent RGD-containing antagonist of **glycoprotein IIb-IIIa and platelet aggregation** inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg .

Cat. No.	Product Name	Target	Research Area

HY-B0686B

Eptifibatide acetate Maximum Cited Publications 7 Publications Verification	Integrin	Cardiovascular Disease
Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity .

HY-B0686

Eptifibatide Maximum Cited Publications 7 Publications Verification	Integrin	Cardiovascular Disease
Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity .

HY-B0686A

Eptifibatide monoacetate	Integrin	Cardiovascular Disease
Eptifibatide monoacetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet **glycoprotein IIb/IIIa receptor**, with anti-platelet activity .

HY-B0686BR

Eptifibatide (acetate) (Standard)	Integrin	Cardiovascular Disease
Eptifibatide (acetate) (Standard) is the analytical standard of Eptifibatide (acetate). This product is intended for research and analytical applications. Eptifibatide acetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity .

HY-P3082

SKF 106760	Peptides	Cardiovascular Disease
SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .

Cat. No.	Product Name	Target	Research Area

HY-P9934

Abciximab 1 Publications Verification C7E3	Integrin	Cardiovascular Disease
Abciximab (C7E3), a chimeric mouse/human monoclonal antibody fragment, is a **glycoprotein (GP) IIb/IIIa** inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-167686

Variabilin Homopisatin	Structural Classification Natural Products Source classification Plants Dalbergia variabilis Fabaceae	Integrin
Variabilin (Homopisatin) is a potent RGD-containing antagonist of **glycoprotein IIb-IIIa and platelet aggregation** inhibitor from the hard tick Dermacentor variabilis. Variabilin potently inhibits platelet aggregation induced by the platelet agonists ADP, collagen, and thrombin receptor peptide SFLLRNP. Variabilin also blocks platelet adhesion to immobilized Fg. In addition, Variabilin inhibits binding of purified human GPIIb-IIIa to immobilized Fg .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

glycoprotein IIb/IIIa receptor

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Natural
Products